Recombinant vector vaccines
Recombinant vector vaccines are experimental vaccines similar to DNA vaccines, but they use an attenuated virus or bacterium to introduce microbial DNA to cells of the body. “Vector” refers to the virus or bacterium used as the carrier. Attenuated bacteria also can be used as vectors. In this case, the inserted genetic material causes the bacteria to display the antigens of other microbes on its surface. In effect, the harmless bacterium mimics a harmful microbe, provoking an immune response.
Researchers are working on both bacterial and viral-based recombinant vector vaccines for HIV, rabies, and measles.
- Attenuated Viruses Used- Response and stimulation
- New techniques
- Vectors
- Recombinant coccidia antigen vaccination
- Others
Related Conference of Recombinant vector vaccines
July 15-16, 2024
7th International Conference on Vaccines, Immunology and Clinical Trials
Amsterdam, Netherlands
Recombinant vector vaccines Conference Speakers
Recommended Sessions
- AIDS Vaccine
- Bacterial Infections in Hiv Patients
- Causes of HIV
- Fungal Infections in Hiv Patients
- Hepatitis & HIV
- HIV Prevention
- HIV Saliva
- HIV testing
- HIV Vaccine
- Hiv vaccine development
- HIV Vaccine Trials
- HIV Vaccines Research
- Immunizations and HIV
- Infectious Diseases
- Malignancies (Cancers) in Hiv Patients
- Neurological Conditions In Hiv Patients
- Preventive HIV Vaccines
- Protozoal Infections In Hiv Patients
- Recombinant vector vaccines
- Safety of Vaccinations
- Specific Vaccines on Hiv Subjects/Patients
- Stages of HIV infection
- STDs in Hiv Patients
- Subunit vaccines
- Therapeutic HIV vaccines
- Transmission of HIV
- Unwanted effects of HIV Vaccines
- Viral Infections In Hiv Patients
Related Journals
Are you interested in
- Animal & Plant Derived Vaccines - Vaccine Immunology 2024 (France)
- Animal Models & Clinical Trials - Vaccine Immunology 2024 (France)
- Antibodies: Engineering & Therapeutics - Vaccine Immunology 2024 (France)
- Antiviral Therapies - Virology Meet 2024 (Austria)
- Basic Immunology - Virology Meet 2024 (Austria)
- Cancer, Malaria & TB Vaccines - Vaccine Immunology 2024 (France)
- Cellular Immunology & Latest Innovations - Vaccine Immunology 2024 (France)
- Challenges in Global Vaccination Programs - Vaccines R&D 2024 (Netherlands)
- Clinical Immunology - Virology Meet 2024 (Austria)
- Clinical Trials: Safety, Efficacy, and Beyond - Vaccines R&D 2024 (Netherlands)
- Combination & Conjugate Vaccines - Vaccine Immunology 2024 (France)
- COVID19 Vaccines - VACCINE CONGRESS 2024 (Spain)
- Current Research & Future Challenges - Vaccine Immunology 2024 (France)
- Cutting-Edge Techniques in Vaccine Manufacturing - Vaccines R&D 2024 (Netherlands)
- DNA & Synthetic Vaccines - Vaccine Immunology 2024 (France)
- Emerging Infectious Diseases and Global Health - VACCINES WORLD 2024 (Canada)
- Emerging Viral Diseases - Virology Meet 2024 (Austria)
- Epidemiology and Public Health - Virology Meet 2024 (Austria)
- Ethical and Societal Aspects of Vaccination - VACCINES WORLD 2024 (Canada)
- Fish & Poultry Vaccines - Vaccine Immunology 2024 (France)
- Gene Editing for Vaccine Development - Vaccines R&D 2024 (Netherlands)
- Geriatric Immunization - Vaccine Immunology 2024 (France)
- Geriatric Vaccines - VACCINE CONGRESS 2024 (Spain)
- Global Vaccine Access - VACCINE CONGRESS 2024 (Spain)
- HIV Vaccines - Vaccine Immunology 2024 (France)
- Immune System and Non-Infectious Diseases - Vaccines R&D 2024 (Netherlands)
- Immunization in Special Populations - VACCINES WORLD 2024 (Canada)
- Immunodiagnostics and Monitoring Immune Responses - VACCINES WORLD 2024 (Canada)
- Immunogenetics and Genomics - Virology Meet 2024 (Austria)
- Immunogenetics and Personalized Vaccinology - VACCINES WORLD 2024 (Canada)
- Immunology and Infectious Diseases: Current Landscape - Vaccines R&D 2024 (Netherlands)
- Immunology of Aging and Vaccination - Vaccines R&D 2024 (Netherlands)
- Immunology of Vaccines - VACCINE CONGRESS 2024 (Spain)
- Immunometabolism - Virology Meet 2024 (Austria)
- Immunopathology and Host-Pathogen Interactions - VACCINES WORLD 2024 (Canada)
- Immunotherapy - Virology Meet 2024 (Austria)
- Immunotherapy: Novel Strategies and Technologies - Vaccines R&D 2024 (Netherlands)
- Infectious Diseases and Immunity - Virology Meet 2024 (Austria)
- Inflammation and Immune Response - Virology Meet 2024 (Austria)
- Innate and Adaptive Immune Responses - VACCINES WORLD 2024 (Canada)
- Innovative Approaches to Vaccine Design - Vaccines R&D 2024 (Netherlands)
- Innovative Immunotherapies - VACCINES WORLD 2024 (Canada)
- Next Generation Vaccines - VACCINE CONGRESS 2024 (Spain)
- Next-Generation Vaccines: Advancements and Challenges - Vaccines R&D 2024 (Netherlands)
- Novel Vaccine Platforms - VACCINE CONGRESS 2024 (Spain)
- One Health Approach - VACCINE CONGRESS 2024 (Spain)
- Paediatric Vaccination - Vaccine Immunology 2024 (France)
- Paediatric Vaccines - VACCINE CONGRESS 2024 (Spain)
- Precision Medicine and Personalized Vaccines - Vaccines R&D 2024 (Netherlands)
- Public Health and Vaccination Programs - VACCINES WORLD 2024 (Canada)
- Public-Private Partnerships for Vaccine Research - Vaccines R&D 2024 (Netherlands)
- Regulatory Guidelines for Vaccine Approval - Vaccines R&D 2024 (Netherlands)
- The Future of Vaccinology: Trends and Prospects - Vaccines R&D 2024 (Netherlands)
- Travel & Edible Vaccines - Vaccine Immunology 2024 (France)
- Vaccination Strategies for Vector-Borne Diseases - VACCINES WORLD 2024 (Canada)
- Vaccine Adjuvants - VACCINE CONGRESS 2024 (Spain)
- Vaccine Clinical Trials - VACCINE CONGRESS 2024 (Spain)
- Vaccine Delivery Systems - VACCINE CONGRESS 2024 (Spain)
- Vaccine Development - Virology Meet 2024 (Austria)
- Vaccine Development and Design - VACCINES WORLD 2024 (Canada)
- Vaccine Development for Emerging Diseases - VACCINE CONGRESS 2024 (Spain)
- Vaccine Economics and Market Access - VACCINES WORLD 2024 (Canada)
- Vaccine Education and Advocacy - VACCINES WORLD 2024 (Canada)
- Vaccine Equity - VACCINE CONGRESS 2024 (Spain)
- Vaccine Financing - VACCINE CONGRESS 2024 (Spain)
- Vaccine Hesitancy - VACCINE CONGRESS 2024 (Spain)
- Vaccine Hesitancy: Causes and Solutions - Vaccines R&D 2024 (Netherlands)
- Vaccine Immunogenicity - VACCINE CONGRESS 2024 (Spain)
- Vaccine Manufacturing - VACCINE CONGRESS 2024 (Spain)
- Vaccine Policy and Regulation - VACCINE CONGRESS 2024 (Spain)
- Vaccine Production & Development - Vaccine Immunology 2024 (France)
- Vaccine Safety - VACCINE CONGRESS 2024 (Spain)
- Vaccine Safety and Adverse Event Monitoring - VACCINES WORLD 2024 (Canada)
- Vaccine Surveillance - VACCINE CONGRESS 2024 (Spain)
- Vaccines - Vaccine Immunology 2024 (France)
- Vaccines & Autism - Vaccine Immunology 2024 (France)
- Vaccines against Drugs - Vaccine Immunology 2024 (France)
- Vaccines against Infectious Diseases - Vaccine Immunology 2024 (France)
- Vaccines Epidemiology - VACCINE CONGRESS 2024 (Spain)
- Vaccines for Immune Mediated Diseases - Vaccine Immunology 2024 (France)
- Vaccines for Non-Communicable Diseases - VACCINES WORLD 2024 (Canada)
- Vaccines for Pregnant Women & Neonates - Vaccine Immunology 2024 (France)
- Vaccines for Unconventional Diseases - Vaccine Immunology 2024 (France)
- Vaccines Immunology - VACCINE CONGRESS 2024 (Spain)
- Vectors, Adjuvants & Delivery Systems - Vaccine Immunology 2024 (France)
- Viral Diagnostics - Virology Meet 2024 (Austria)
- Viral Genomics and Evolution - Virology Meet 2024 (Austria)
- Viral Immunology - Virology Meet 2024 (Austria)
- Viral Pathogenesis - Virology Meet 2024 (Austria)
- Viral Vaccines - Virology Meet 2024 (Austria)